Department of Defense explores AI-enabled infection control

The technology examines vital signs and other biomarkers to predict the likelihood of infection


The technology, developed in part by the U.S. Department of Defense (DoD), examines vital signs and other biomarkers to predict the likelihood of infection up to 48 hours ahead of clinical suspicion, according to an article on the Healthcare IT News website.

The technology is intended for U.S. service members but expected to be used widely by civilians. 

The healthcare technology company, Royal Philips, and the DoD collaborated on the 18-month project.

The technology is expected to be broadly applicable to civilian healthcare settings. It will eventually be used in scenarios where vital signs and biomarkers fluctuate, like during physical exertion and heat stress.

Read the article.



October 29, 2019


Topic Area: Infection Control


Recent Posts

Disinfectant Dispensers in Healthcare Facilities Often Fail to Deliver Safe Concentrations: Study

Study of 10 hospitals finds 90 percent have at least one dispenser delivering disinfectants at incorrect concentrations.


Duke University Health System Receives $50 Million for Proton Beam Therapy Center

The donation is the largest philanthropic gift received by Duke University Health System.


UT Southwestern Experiences Data Breach Through Calendar Tool

The incident occurred in October.


Protecting Patient Data: Strategies and Tactics

As cyber threats and breaches grow, healthcare organizations and facilities need a better approach to cybersecurity.


Duke Health to Acquire Lake Norman Regional Medical Center

The closing is projected for the first quarter of 2025.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.